ArticleToxics2026
Aggregate Consumer Exposure and Risk Assessment in the EU-A Case Study.
Article in Toxics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Consumer exposure to chemicals in the EU is currently assessed separately for different products without aggregating exposure from different sources. A more integrated ap proach represents a promising opportunity to improve comprehensive risk evaluation and transparency across the value chain. This study develops aggregate consumer expo sure and risk assessment methods that involve calculation of exposure and risk for each pathway using the risk characterization ratio (RCR) as a uniform risk metric. Aggregate risk is obtained by adding up pathway-specific RCRs. The developed methodology re presents a new approach by evaluating exposure of seven population groups via all path ways and by using key input values normalized to body weight to reflect population-specific differences. The study demonstrates the practical applicability of the methodol o gy by assessing consumer exposure to the antioxidant ethylene bis[3,3-bis(3-tert-butyl-4-hydroxyphenyl)butyrate] (Hostanox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.